Shots:

• The P-III FIGARO-DKD study involves assessing the efficacy and safety of finerenone (10/20mg- PO- qd) + SoC vs PBO + SoC in ~7400 patients with CKD and T2D at 1-000+ sites across 47 countries globally
• The study resulted in meeting its 1EPs i.e reduction in the composite risk of time to the first occurrence of CV death and non-fatal CV events or outcomes in patients with CKD and T2D
• The FDA currently reviews the NDA for Priority Review based on the P-III FIDELIO-DKD study while the data from the FIGARO-DKD study will be presented at an upcoming scientific meeting. Finerenone is an investigational non-steroidal- selective mineralocorticoid receptor antagonist

  Ref: BUSINESS WIRE | Image: Bayer